Literature DB >> 17121790

Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo.

Zachary C Hartman1, Anne Kiang, Ruth S Everett, Delila Serra, Xiao Y Yang, Timothy M Clay, Andrea Amalfitano.   

Abstract

Nearly 50 years ago, the discovery of interferon prompted the notion that host cells innately respond to viral invasion. Since that time, technological advances have allowed this response to be extensively characterized and dissected in vitro. However, these advances have only recently been applied to highly complex, in vivo biological systems. To this end, we exploited high-titer adenovirus (Ad) vectors to globally investigate the innate immune response to nonenveloped viral infection in vivo. Our results indicated a potent cellular transcriptome response shortly after infection, with global assessments revealing significant dysregulation in approximately 15% of the measured transcripts derived from Ad vector-transduced tissue. Bioinformatics-based transcriptome analysis revealed a complex innate response to Ad infection, with induction of proinflammatory responses (and suppression of metabolism and mitochondrial genes) akin to those observed when mice are challenged with lipopolysaccharide. Despite this commonality, there were many unique aspects of the Ad-dependent transcriptome response, including the upregulation of several RNA regulatory mechanisms and apoptosis-related pathways, accompanied by the suppression of lysosomal and endocytic genes. Our results also implicated the Toll-like receptors (TLRs) in these responses, prompting specific investigations into this pathway. By using MyD88KO mice, our results confirmed that Ad-induced dysregulation of five functionally related gene clusters are significantly dependent on this TLR adaptor gene. MyD88 deficiency also resulted in significantly diminished, although not abolished, adaptive and acute-phase immune responses to Ad, confirming the transcriptome data, as well as specifically identifying MyD88 as a significant Ad immunity amplifier and regulator in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17121790      PMCID: PMC1797572          DOI: 10.1128/JVI.01936-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

Review 1.  Innate immune sensing and its roots: the story of endotoxin.

Authors:  Bruce Beutler; Ernst Th Rietschel
Journal:  Nat Rev Immunol       Date:  2003-02       Impact factor: 53.106

2.  Innate and acquired immunity intersect in a global view of the acute-phase response.

Authors:  Joo-Yeon Yoo; Stephen Desiderio
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-22       Impact factor: 11.205

Review 3.  Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy.

Authors:  Andrea Amalfitano; Robin J Parks
Journal:  Curr Gene Ther       Date:  2002-05       Impact factor: 4.391

4.  Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein.

Authors:  B L Hodges; D Serra; H Hu; C A Begy; J S Chamberlain; A Amalfitano
Journal:  J Gene Med       Date:  2000 Jul-Aug       Impact factor: 4.565

5.  Identifying biological themes within lists of genes with EASE.

Authors:  Douglas A Hosack; Glynn Dennis; Brad T Sherman; H Clifford Lane; Richard A Lempicki
Journal:  Genome Biol       Date:  2003-09-11       Impact factor: 13.583

6.  Strategic attack on host cell gene expression during adenovirus infection.

Authors:  Hongxing Zhao; Fredrik Granberg; Ludmila Elfineh; Ulf Pettersson; Catharina Svensson
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  WntD is a feedback inhibitor of Dorsal/NF-kappaB in Drosophila development and immunity.

Authors:  Michael D Gordon; Marc S Dionne; David S Schneider; Roel Nusse
Journal:  Nature       Date:  2005-08-17       Impact factor: 49.962

Review 8.  A genome-wide analysis of the acute-phase response and its regulation by Stat3beta.

Authors:  Stephen Desiderio; Joo-Yeon Yoo
Journal:  Ann N Y Acad Sci       Date:  2003-04       Impact factor: 5.691

9.  Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors.

Authors:  R S Everett; B L Hodges; E Y Ding; F Xu; D Serra; A Amalfitano
Journal:  Hum Gene Ther       Date:  2003-12-10       Impact factor: 5.695

Review 10.  Molecular basis of the inflammatory response to adenovirus vectors.

Authors:  Q Liu; D A Muruve
Journal:  Gene Ther       Date:  2003-06       Impact factor: 5.250

View more
  78 in total

1.  Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine.

Authors:  Basav N Hangalapura; Dinja Oosterhoff; Tarun Gupta; Jan de Groot; Pepijn G J T B Wijnands; Victor W van Beusechem; Joke den Haan; Thomas Tüting; Alfons J M van den Eertwegh; David T Curiel; Rik J Scheper; Tanja D de Gruijl
Journal:  Vaccine       Date:  2011-01-25       Impact factor: 3.641

2.  TRIF, and TRIF-interacting TLRs differentially modulate several adenovirus vector-induced immune responses.

Authors:  D M Appledorn; S Patial; S Godbehere; N Parameswaran; A Amalfitano
Journal:  J Innate Immun       Date:  2009-03-04       Impact factor: 7.349

3.  Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo.

Authors:  Sergey S Seregin; Yasser A Aldhamen; Daniel M Appledorn; Zachary C Hartman; Nathaniel J Schuldt; Jeannine Scott; Sarah Godbehere; Haixiang Jiang; Michael M Frank; Andrea Amalfitano
Journal:  Blood       Date:  2010-05-28       Impact factor: 22.113

4.  Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors.

Authors:  Elizabeth G Rhee; Joseph N Blattman; Sudhir P Kasturi; R Phelps Kelley; David R Kaufman; Diana M Lynch; Annalena La Porte; Nathaniel L Simmons; Sarah L Clark; Bali Pulendran; Philip D Greenberg; Dan H Barouch
Journal:  J Virol       Date:  2010-10-20       Impact factor: 5.103

5.  Sublingual administration of an adenovirus serotype 5 (Ad5)-based vaccine confirms Toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell-mediated responses against HIV antigens despite preexisting Ad5 immunity.

Authors:  Daniel M Appledorn; Yasser A Aldhamen; Sarah Godbehere; Sergey S Seregin; Andrea Amalfitano
Journal:  Clin Vaccine Immunol       Date:  2010-11-17

6.  High persistence rate of hepatitis B virus in a hydrodynamic injection-based transfection model in C3H/HeN mice.

Authors:  Xiu-Hua Peng; Xiao-Nan Ren; Li-Xiang Chen; Bi-Sheng Shi; Chun-Hua Xu; Zhong Fang; Xue Liu; Jie-Liang Chen; Xiao-Nan Zhang; Yun-Wen Hu; Xiao-Hui Zhou
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

7.  Polymorphisms of the SAMHD1 gene are not associated with the infection and natural control of HIV type 1 in Europeans and African-Americans.

Authors:  Sirena Coon; Danxin Wang; Li Wu
Journal:  AIDS Res Hum Retroviruses       Date:  2012-06-01       Impact factor: 2.205

Review 8.  Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications.

Authors:  Zachary C Hartman; Daniel M Appledorn; Andrea Amalfitano
Journal:  Virus Res       Date:  2007-11-26       Impact factor: 3.303

9.  Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy.

Authors:  Sergey S Seregin; Daniel M Appledorn; Aaron J McBride; Nathaniel J Schuldt; Yasser A Aldhamen; Tyler Voss; Junping Wei; Matthew Bujold; William Nance; Sarah Godbehere; Andrea Amalfitano
Journal:  Mol Ther       Date:  2009-01-27       Impact factor: 11.454

10.  Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas.

Authors:  Mirjana Urosevic; Kazuyasu Fujii; Bastien Calmels; Elisabeth Laine; Nikita Kobert; Bruce Acres; Reinhard Dummer
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.